{"product_id":"new-product-581622","title":"Bcl-10 Monoclonal Antibody","description":"\u003cp\u003eThis gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants.\u003c\/p\u003e\n\u003cp\u003eIntroducing the BCL-10 Monoclonal Antibody, a cutting-edge biotechnological innovation designed to revolutionize the field of immunotherapy. This meticulously engineered antibody is specifically developed to target and neutralize the B-cell lymphoma\/leukemia 10 (BCL-10) protein, a crucial component in various signaling pathways associated with cancer progression.\u003cbr\u003e\u003cbr\u003eCrafted with utmost precision and utilizing state-of-the-art techniques, the BCL-10 Monoclonal Antibody exhibits exceptional specificity and affinity towards its target, ensuring optimal therapeutic efficacy. Its monoclonal nature guarantees a consistent and reliable performance, enabling researchers and clinicians to confidently explore its potential applications in diagnostic assays, research studies, and therapeutic interventions.\u003cbr\u003e\u003cbr\u003eThe BCL-10 Monoclonal Antibody's unrivaled ability to selectively bind to the BCL-10 protein offers a multitude of advantages. By inhibiting the aberrant signaling cascades mediated by BCL-10, this antibody holds immense promise in suppressing tumor growth, preventing metastasis, and enhancing the overall prognosis of cancer patients. Furthermore, its potential as a diagnostic tool allows for accurate identification and classification of BCL-10-associated malignancies, facilitating personalized treatment strategies.\u003cbr\u003e\u003cbr\u003eThis groundbreaking product is meticulously manufactured in compliance with stringent quality control measures, ensuring its purity, stability, and reproducibility. Its formulation is optimized to facilitate ease of use, enabling seamless integration into various experimental protocols and clinical settings.\u003cbr\u003e\u003cbr\u003eIn summary, the BCL-10 Monoclonal Antibody represents a remarkable advancement in the realm of immunotherapy, poised to revolutionize cancer treatment and research. With its exceptional specificity, reliability, and potential therapeutic benefits, this antibody stands as a beacon of hope in the fight against BCL-10-associated malignancies. Embrace the future of precision medicine with the BCL-10 Monoclonal Antibody and unlock new possibilities in the pursuit of improved patient outcomes.\u003c\/p\u003e","brand":"BT Lab","offers":[{"title":"100ul \/ Mouse \/ Primary antibody","offer_id":47548571910424,"sku":"BT-MCA0204","price":300.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/BT_Lab_723c673b-a93e-46cb-a573-2466c85f2dae.png?v=1705696547","url":"https:\/\/danabiosci.com\/products\/new-product-581622","provider":"Dana Bioscience","version":"1.0","type":"link"}